Linagliptin, a selective DPP-4 inhibitor, inhibits DPP-4, increases incretin levels, lowers glucagon, and improves glycaemic control in patients with Type 2 diabetes.

Research output: Contribution to journalJournal articleResearchpeer-review

T Rauch, U Graefe-Mody, Carolyn F. Deacon, A Ring, Jens Juul Holst, H-J Woerle, KA Dugi, T Heise

Original languageEnglish
JournalDiabetes Therapy
Issue number1
Pages (from-to)10
Publication statusPublished - 2012

ID: 40389687